ABSTRACTChronic, biofilm-like infections by the opportunistic pathogenPseudomonas aeruginosaare a major cause of mortality in cystic fibrosis (CF) patients. While much is known aboutP. aeruginosafrom laboratory studies, far less is understood about what it experiencesin vivo. Iron is an important environmental parameter thought to play a central role in the development and maintenance ofP. aeruginosainfections, for both anabolic and signaling purposes. Previous studies have focused on ferric iron [Fe(III)] as a target for antimicrobial therapies; however, here we show that ferrous iron [Fe(II)] is abundant in the CF lung (~39 µM on average for severely sick patients) and significantly correlates with disease severity (ρ = −0.56,P= 0.004), whereas ferric iron does not (ρ = −0.28,P= 0.179). Expression of theP. aeruginosagenesbqsRS, whose transcription is upregulated in response to Fe(II), was high in the majority of patients tested, suggesting that increased Fe(II) is bioavailable to the infectious bacterial population. Because limiting Fe(III) acquisition inhibits biofilm formation byP. aeruginosain various oxicin vitrosystems, we also tested whether interfering with Fe(II) acquisition would improve biofilm control under anoxic conditions; concurrent sequestration of both iron oxidation states resulted in a 58% reduction in biofilm accumulation and 28% increase in biofilm dissolution, a significant improvement over Fe(III) chelation treatment alone. This study demonstrates that the chemistry of infected host environments coevolves with the microbial community as infections progress, which should be considered in the design of effective treatment strategies at different stages of disease.IMPORTANCEIron is an important environmental parameter that helps pathogens thrive in sites of infection, including those of cystic fibrosis (CF) patients. Ferric iron chelation therapy has been proposed as a novel therapeutic strategy for CF lung infections, yet until now, the iron oxidation state has not been measured in the host. In studying mucus from the infected lungs of multiple CF patients from Europe and the United States, we found that ferric and ferrous iron change in concentration and relative proportion as infections progress; over time, ferrous iron comes to dominate the iron pool. This information is relevant to the design of novel CF therapeutics and, more broadly, to developing accurate models of chronic CF infections.
Ferrous Iron Is a Significant Component of Bioavailable Iron in Cystic Fibrosis Airways
